Mill Capital Management LLC Invests $28.15 Million in Thermo Fisher Scientific Inc. $TMO

Mill Capital Management LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 56,154 shares of the medical research company’s stock, valued at approximately $28,153,000. Thermo Fisher Scientific accounts for about 1.9% of Mill Capital Management LLC’s investment portfolio, making the stock its 17th biggest holding.

Other hedge funds also recently added to or reduced their stakes in the company. Laraway Financial Advisors Inc acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $1,097,000. Cornerstone Capital Inc. acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth $24,571,000. Northstar Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth $287,000. Merit Financial Group LLC boosted its holdings in Thermo Fisher Scientific by 47.9% in the second quarter. Merit Financial Group LLC now owns 21,997 shares of the medical research company’s stock valued at $11,028,000 after purchasing an additional 7,125 shares during the period. Finally, Diversified Trust Co. grew its stake in Thermo Fisher Scientific by 71.1% during the 2nd quarter. Diversified Trust Co. now owns 17,214 shares of the medical research company’s stock worth $8,630,000 after purchasing an additional 7,155 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of analyst reports. Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. Barclays boosted their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective on the stock. Finally, HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $619.41.

Insider Transactions at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,053 shares of company stock valued at $30,643,589 over the last quarter. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

TMO stock opened at $588.17 on Monday. The business has a 50 day moving average price of $529.37 and a 200 day moving average price of $508.75. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock has a market cap of $217.48 billion, a price-to-earnings ratio of 31.64, a PEG ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.